BCL2L11 and cancer: In addition, downregulation of the MEK/ERK pathway by SHP099 was sufficient to upregulate the BH3-only protein BIM, a major effector protein of this pathway in cancer (Faber et al., 2012; Sale and Cook, 2013) in both sensitive and resistant NBs (Figure 2A).